Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

Urticaria affects both children and adults, with chronic cases more common in women, and often presents in emergency or dermatology settings. Conditions like vasculitic urticaria, erythema ...

High-dose aflibercept offers extended dosing intervals for DME and wet AMD, with sustained visual and anatomical improvements. The PULSAR and PHOTON trials showed efficacy in maintaining vision ...

In our view, barzolvolimab may need to match or exceed the approximately 59% histologic remission rate seen with dupilumab, the only FDA-approved biologic for EoE, in Phase 3 to secure a ...

MoA International Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's average 10 ...

The Global Burden of Disease (GBD) Study 2021 reported 44.84 million disability-adjusted life years (DALYs) because of skin and subcutaneous diseases. Researchers utilized data from the GBD Study ...

MoA All America Fund earns an Average Process Pillar rating. The main driver of the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average 10 ...

Patients will be administered KT-621 once daily for 28 days. The key study objective is to show that robust STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing ...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence. It’s common for ...